Seeking Alpha

Positive Phase 3 results for empagliflozin

  • Eli Lilly (LLY -0.3%) and development partner Boehringer Ingelheim announce positive top-line results from two Phase 3 trials of empagliflozin as a treatment for type 2 diabetes.
  • In a two-year 1,545-patient study comparing the safety and efficacy of empagliflozin with glimepiride each in combination with metformin, at 104 weeks patients in the empagliflozin cohort had significantly greater reductions in A1C, body weight and systolic and diastolic blood pressure from baseline compared to the glimepiride cohort. There were also significantly fewer hypoglycemic events in the empagliflozin group.
  • In a 52-week placebo-controlled study of obese inadequately controlled type 2 diabetes patients on multiple daily insulin injections with or without metformin, empagliflozin significantly reduced A1C levels from baseline compared to the control group. Patients in the test group lost an average of 2 kg of weight versus a 0.4 kg average gain in the placebo group.
Comments (1)
  • Doc 224899
    , contributor
    Comments (919) | Send Message
    If Lilly wanted to make some profits, they could rename this drug, and call it something that could be remembered and pronounced by native speakers of Standard American English.
    16 Jun, 03:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: